Fig. 4From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a studya Glutaminyl cyclase activity (mU/L): change from baseline at end of treatment. Per protocol population. b In-vivo target occupancy calculated from PQ912 levels. PQ912 treated, per protocol (PP) populationBack to article page